Lung Cancer

Expert discussions outline treatment algorithms across lung cancer, including NSCLC and SCLC, integrating evolving data for targeted, immunotherapy, and chemotherapy approaches.

How To Select Between Treatment Options for BRAF V600E–Mutated NSCLC

Gregory Riely, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

The Frontline Treatment Algorithm for Metastatic NSCLC Without Actionable Mutations

Chirstine Garcia, MD, MPH, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Frontline Treatments for Metastatic NSCLC With Actionable Mutations

Eric Singhi, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Standard of Care Curative Treatments for Early-Stage NSCLC

Sanjay Popat, FRCP, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Standard of Care in SCLC: Treatment Across Limited- and Extensive-Stage Disease

Jacob Sands, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Reviewing Early-Stage NSCLC Treatments in 2025

Deepa Rangachari, MD

Frontline Treatment for Metastatic EGFR-Mutated NSCLC

Susan Scott, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Selecting Up-Front Treatments for NSCLC with Targetable Mutations

Susan Scott, MD

Recent and Upcoming Advancements in Treatment Options for SCLC

Ticiana Leal, MD

Frontline Treatment of Metastatic NSCLC Without Actionable Mutations

Mark Awad, MD, PhD